Business
Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of differentiated targeted radiotherapies, today announced that it will present two abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, 2026 in San Diego, California.
About this update from Actinium Pharmaceuticals, Inc. (delaware)
[{"type":"text","content":"AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology Applications","length":119,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of differentiated targeted radiotherapies, today announced that it will present two abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, 2026 in San Diego, California.","length":399,"tagName":"p"},{"type":"image","alt":"FINAL LOGO ACTINIUM PHARMA - 1 (PRNewsfoto/Actinium Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"FINAL LOGO ACTINIUM PHARMA - 1 (PRNewsfoto/Actinium Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/eb2937f11974a18d93e636c38ac22747"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tI3JaOV1.VRR07OtHxFB0A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/eb2937f11974a18d93e636c38ac22747","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/730678/Actinium_Pharmaceuticals_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Both abstracts are scheduled for presentation in the Experimental and Molecular Therapeutics category under the session titled Radiopharmaceutical Platforms for Theranostic Precision Oncology on April 21, 2026.","length":210,"tagName":"p"},{"type":"text","content":"In accordance with AACR embargo policies, details of the abstracts, including titles and full text, will become publicly available on March 17, 2026, at 4:30 PM ET via the AACR Online Program Planner.","length":200,"tagName":"p"},{"type":"text","content":"Presentation Details","length":20,"tagName":"p"},{"type":"text","content":"Presentation #1: ","length":16,"tagName":"p"},{"type":"text","content":"Session Category: Experimental and Molecular TherapeuticsSession Title: Radiopharmaceutical Platforms for Theranostic Precision OncologySession Date & Time: April 21, 2026 | 2:00 PM – 5:00 PM PTLocation: Poster Section 16Poster Board Number: 18Poster Number: 5824","length":272,"tagName":"p"},{"type":"text","con...